Searchable abstracts of presentations at key conferences in endocrinology

ea0044ec1.4 | Early Career Symposium: Launching your career whatever it may be | SFEBES2016

The route to floristry via medicine – forging a clinical academic career as a trainee

Mitchell Anna L

In recent years, the integrated clinical academic pathway has made a previously seemingly chaotic career pathway far more organised. This is now a well-trodden path; for those interested in research, there are opportunities to join this pathway at every stage, from academic foundation programmes through to fellowships aimed at those post-CCT. Combining clinical training in endocrinology (and not forgetting diabetes and general internal medicine too) with research, whether basi...

ea0077p144 | Adrenal and Cardiovascular | SFEBES2021

An analysis of full blood count parameters in a cohort of patients with classical congenital adrenal hyperplasia

Howarth Sophie , Devine Kerri , Mitchell Anna L

Background: Hyperandrogenism in congenital adrenal hyperplasia (CAH) is associated with virilisation in female patients and subfertility in both male and female patients. However, little is known regarding the association of hyperandrogenaemia with polycythaemia. We evaluate the association between the adrenal hormone profile and haematocrit (HCT)/haemoglobin (Hb) in a cohort of patients with classical CAH.Methods: Single centre retrospective analysis of...

ea0050p396 | Thyroid | SFEBES2017

Association of a promoter BAFF polymorphism in Graves’ disease

Lane Laura C , Allinson Kathleen , Cordell Heather J , Mitchell Anna L , Pearce Simon

Introduction: B lymphocyte activating factor (BAFF), a member of the tumour necrosis factor family, is essential for B cell activation, differentiation and survival. It promotes autoantibody production and as Graves’ disease is caused by thyroid stimulating autoantibodies, it is an excellent functional candidate gene. Indeed, elevated serum BAFF levels have been found in patients with several autoimmune diseases, including Graves’ disease (GD). The T al...

ea0050p396 | Thyroid | SFEBES2017

Association of a promoter BAFF polymorphism in Graves’ disease

Lane Laura C , Allinson Kathleen , Cordell Heather J , Mitchell Anna L , Pearce Simon

Introduction: B lymphocyte activating factor (BAFF), a member of the tumour necrosis factor family, is essential for B cell activation, differentiation and survival. It promotes autoantibody production and as Graves’ disease is caused by thyroid stimulating autoantibodies, it is an excellent functional candidate gene. Indeed, elevated serum BAFF levels have been found in patients with several autoimmune diseases, including Graves’ disease (GD). The T al...

ea0044p236 | Thyroid | SFEBES2016

Increasing awareness of Graves’ orbitopathy with “Early Warning” cards – a TEAMeD multicentre quality improvement project

Mitchell Anna L , Zammitt Nicola , Ajjan Ramzi , Vaidya Bijay , Hickey Janis , Perros Petros , Dayan Colin

Background: Clinically significant Graves’ orbitopathy (GO) develops in 20% of those with Graves’ Disease (GD). Up to 90% of cases present at the same time as, or after, hyperthyroidism develops. Most cases of GD in the UK are managed in endocrinology clinics. Despite this, patients report significant delays before a correct diagnosis of GO is made. We argued that measures to increase awareness of the early signs of GO in those with GD and establishing a fast-track r...

ea0038p403 | Steroids | SFEBES2015

Immunogenicity in AAD patients treated with depot tetracosactide

Davis Joanna L , Napier Catherine , Mitchell Anna L , Gan Earn H , Pearce Simon H S

ACTH is a 39 amino acids polypeptide which stimulates adrenocortical steroid production. The N-terminal segment of ACTH(1–24) is biologically active and the C-terminal is considered to have greater antigenicity. In one previous (‘RoSA’) and one current (‘RADS2’) clinical trial synthetic ACTH (zinc tetracosactide; depot synacthen) was administered to autoimmune Addison’s disease (AAD) patients to stimulate adrenocortical regeneration. 4/13 RoSA pat...

ea0031p327 | Steroids | SFEBES2013

The role of anti-ACTH1–24 antibodies in synacthen-related adverse events

Gan Earn H , MacArthur Katie , Mitchell Anna L , Crock Patricia , Bensing Sophie , Pearce Simon H S

Background: Immune responses to self-peptides should not generally occur. However, four of 12 autoimmune Addison’s disease (AAD) patients developed adverse reactions immediately after synacthen injections, following repeated subcutaneous synacthen injections during a clinical trial (RoSA study). We wondered if these adverse effects were due to the production of anti-synacthen (ACTH1–24) antibodies.Methods: We evaluated the presence o...

ea0094p234 | Neuroendocrinology and Pituitary | SFEBES2023

The utility of routine fasting gut hormone assessment in asymptomatic individuals with Multiple Endocrine Neoplasia Type 1 (MEN1)

Muhammad Tahir Chohan Dr , Chris Boot Dr , Anna L Mitchell Dr

Background: Secretory pancreatic neuroendocrine tumours (PanNET) are common in MEN1. The MEN1 Clinical Practice guideline (Thakker, 2012) recommends annual assessment of fasting gut hormones (FGH) with annual pancreatic imaging for routine NET surveillance in MEN1.Study aim: To determine whether FGH (gastrin, glucagon, somatostatin, pancreatic polypeptide, VIP, insulin, chromogranin-A) in a cohort of asymptomatic individ...

ea0034p166 | Growth and development | SFEBES2014

Differential effects of grazing and meal feeding on skeletal growth and femoral strength in male rats

Tilston Thomas W , Hopkins Anna L , Brown Richard C , Arms-Williams Bradley , Evans Sam L , Wells Timothy

The pattern of food consumption has a profound influence on metabolic hormone secretion, but until recently only crude manipulations of feeding events have been possible in rodents. Using a CLAMS-based system to overcome this problem, we have investigated the effect of 3 weeks of grazing (consumption of 1/24th of the total daily food intake of ad libitum-fed controls every 30 min during the dark phase (18.00–06.00 h)) and meal feeding (three 1-h periods of ad...

ea0059oc5.2 | Adrenal | SFEBES2018

Residual adrenal function in autoimmune addison s disease effect of dual therapy with rituximab and depot tetracosactide

Napier Catherine , Gan Earn H , Mitchell Anna L , Gilligan Lorna C , Rees Aled , Moran Carla , Chatterjee Krishna , Vaidya Bijay , Arlt Wiebke , Pearce Simon HS

In patients with autoimmune Addison’s disease (AAD), exogenous glucocorticoid (GC) therapy is an imperfect substitute for physiological GC secretion; patients on long-term steroid replacement have increased morbidity, reduced life expectancy and poorer quality of life. Recent early-phase studieshave demonstrated that some endogenous steroidogenic function – Residual Adrenal Function (RAF) - is maintained at the point of diagnosis in a proportion of AAD patients; this...